UBS Group’s VanEck Biotech ETF BBH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2015
Q1
– Sell
-3,300
Closed -$381K – 8808
2014
Q4
$381K Buy
3,300
+3,000
+1,000% +$338K ﹤0.01% 4433
2014
Q3
$32K Buy
+300
New +$30.4K ﹤0.01% 7380

Other funds holding BBH

UBS Group's BBH Position: Q3 2026 in Review

UBS Group reduced its VanEck Biotech ETF (BBH) stake by 7.8% in Q3 2026, selling an estimated $276K and leaving 14,575 shares worth $3.56M. The position accounts for ﹤0.01% of the portfolio, ranked #4428.

UBS Group first reported a position in BBH in Q2 2013 and has held it in 54 quarters since. The position peaked at $24.4M in Q3 2017. 123 funds tracked by Wall St. Rank hold BBH as of Q3 2026.

  • UBS Group held 14,575 shares of VanEck Biotech ETF worth $3.56M as of Q3 2026.
  • UBS Group sold 1,234 VanEck Biotech ETF shares in Q3 2026, an estimated $276K.
  • VanEck Biotech ETF made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #4428 holding.
  • UBS Group first reported a position in VanEck Biotech ETF in Q2 2013 and has held it in 54 quarters since.
  • UBS Group's VanEck Biotech ETF position peaked at $24.4M in Q3 2017.
  • 123 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.